Testosterone News and Research

Latest Testosterone News and Research

Repros Therapeutics second-quarter net loss decreases to $1.3 million

Repros Therapeutics Inc. today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

CPEX reports $1.2M second-quarter net income vs $1.2M net loss year earlier

CPEX Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. For the quarter CPEX reported revenues of $5.8 million and net income of $1.2 million.

9 Aug 2010

GTx second-quarter net loss increases to $12.9 million

GTx, Inc. today reported financial results for the second quarter of 2010. The net loss for the quarter ended June 30, 2010 was $12.9 million compared with a net loss of $11.3 million for the quarter ended June 30, 2009. The net loss for the second quarter of 2010 included a $1.7 million non-cash impairment charge related to the conclusion of the Phase III clinical trial of toremifene 20 mg.

9 Aug 2010

Repros Therapeutics receives positive feedback from FDA for Androxal

Repros Therapeutics Inc. today announced that the Company has received positive written feedback from the FDA (the "Agency") regarding the Company's drug candidate Androxal. The Agency concurred with Repros' indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility.

9 Aug 2010

Columbia second-quarter net revenues from progesterone products increase 48% to $8.4 million

Columbia Laboratories, Inc. today announced financial results for the three- and six-month periods ended June 30, 2010.

5 Aug 2010

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Endo Pharmaceuticals today reported financial results for the second quarter 2010. Total revenues during the second quarter of 2010 increased 6 percent to $396.5 million, compared with $373.1 million in the same quarter of 2009. Net income for the three months ended June 30, 2010 was $51.5 million, compared with $30.0 million in the comparable 2009 period.

30 Jul 2010

AB SCIEX collaborates with CDC to improve laboratory hormone testing technique

AB SCIEX, a global leader in life science analytical technologies, today announced a collaboration with the Centers for Disease Control and Prevention (CDC) and the CDC Foundation to facilitate the use of mass spectrometry technologies in clinical laboratories for hormone testing. This collaboration is intended to help support the CDC's Hormone Standardization Project for improving the reliability of laboratory results used to help assess disease risk and monitor treatment.

28 Jul 2010

Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients

Antares Pharma, Inc. announced today positive results from its Phase 3 study of Anturol Gel in patients with overactive bladder. The study met its primary endpoint of a statistically significant reduction in urinary incontinence episodes for both doses studied.

28 Jul 2010

Researchers block central pathway for prostate cancer progression

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.

21 Jul 2010

Scientists find way to block androgens, halt tumor progression in prostate cancer

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens. Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth.

21 Jul 2010

Clinical trial initiated to evaluate LibiGel on cognitive function in menopausal women

BioSante Pharmaceuticals, Inc. today announced the initiation of a LibiGel (testosterone gel) clinical trial to evaluate its effect on cognitive function in menopausal women. The trial is a randomized, 6-month comparison of the effect of LibiGel compared to placebo treatment on a variety of learning and memory tasks. The study is being conducted by Dr. Susan Davis, Professor of Women's Health, Department of Medicine, Monash University Women's Health Program in Australia.

13 Jul 2010

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract, SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia.

13 Jul 2010

Researchers develop first model of hormone-induced human prostate cancer initiation and progression

Progress toward understanding the role of sex hormones in the growth of prostate cancer—the most common cancer in U.S. men—has been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression.

2 Jul 2010

Older men with high testosterone levels more likely to have heart attacks

A large U.S. multicenter study shows that older men with higher testosterone levels are more likely to have a heart attack or other cardiovascular disease in the future. The results were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

Individual variants of environmental toxins can affect body's hormone systems: Research

Marianne Kraugerud's doctoral research has led to the discovery that individual variants of the environmental pollutants PCB and PFC can affect several of the body's hormone systems in a more complex way than previously supposed. Humans and animals are constantly exposed to these toxins through the food they eat and the air they breathe. Kraugerud concludes that the impact of these pollutants should be taken into account when carrying out risk appraisals of PCB and PFC.

1 Jul 2010

Endo responds to FDA Complete Response letter for FORTESTA NDA

Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.

1 Jul 2010

New guide to get pregnant

Infertility affects about 7 million Americans -- that's about one in six couples during their childbearing years. There are many reasons for infertility, with equal chances it's his medical issue as it is hers. A new book, "A Baby at Last!: The Couples' Complete Guide to Getting Pregnant" (Fireside Books, Simon and Schuster), points the way for couples to get past the emotionally wrenching obstacle of infertility and finally bring home their bundle of joy.

1 Jul 2010

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

BioSante Pharmaceuticals, Inc. announced today positive results in a Phase II study of the Pill-Plus "triple hormone" oral contraceptive (OC). Results showed an increase in the frequency of sexual activity (p< 0.05) and reduced frequency of rejection of initiation of sexual activity by partner (p< 0.05).

30 Jun 2010

Maternal alcohol consumption impacts semen concentration in male offspring

Mothers who drink alcohol while they are pregnant may be damaging the fertility of their future sons, according to new research to be presented at the 26th annual meeting of the European Society of Human Reproduction and Embryology in Rome today (Tuesday 29 June).

29 Jun 2010

BioSante joins Russell 3000 Index

BioSante Pharmaceuticals, Inc. today announced it has been added to the broad-market Russell 3000 Index as part of Russell Investments' recent reconstitution of its comprehensive set of U.S. and global equity indexes which occurred after market close on June 25, 2010.

28 Jun 2010

Testosterone News and Research

Latest Testosterone News and Research

Repros Therapeutics second-quarter net loss decreases to $1.3 million

CPEX reports $1.2M second-quarter net income vs $1.2M net loss year earlier

GTx second-quarter net loss increases to $12.9 million

Repros Therapeutics receives positive feedback from FDA for Androxal

Columbia second-quarter net revenues from progesterone products increase 48% to $8.4 million

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

AB SCIEX collaborates with CDC to improve laboratory hormone testing technique

Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients

Researchers block central pathway for prostate cancer progression

Scientists find way to block androgens, halt tumor progression in prostate cancer

Clinical trial initiated to evaluate LibiGel on cognitive function in menopausal women

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

Researchers develop first model of hormone-induced human prostate cancer initiation and progression

Older men with high testosterone levels more likely to have heart attacks

Individual variants of environmental toxins can affect body's hormone systems: Research

Endo responds to FDA Complete Response letter for FORTESTA NDA

New guide to get pregnant

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

Maternal alcohol consumption impacts semen concentration in male offspring

BioSante joins Russell 3000 Index

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Testosterone News and Research

Latest Testosterone News and Research

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in